Biotech vaccines' problematic promise.

Malaria vaccines: the failed promise.

Vaccines: facing complex problems with the promise of immunology.

Peptide vaccines for hematological malignancies: a missed promise?

Emerging cancer vaccines: the promise of genetic vectors.

The promise and challenge of epitope-focused vaccines.

Patent patterns in biotech.

Biotech grows in Hong Kong.

Bridging tech and biotech.

Biotech lobby pressure EC.

2Q14-Biotech corrected.

Fourth-quarter biotech job picture.

Do recombinant-engineered nanoparticle vaccines hold promise for the prevention of respiratory syncytial virus?

Broadly neutralizing antibodies and the promise of universal vaccines: where are we now?

South Asia symposium on pneumococcal disease and the promise of vaccines - Meeting report.

Second-quarter biotech job picture.

2013--Biotech back in the saddle.

Public biotech 2013--the numbers.

FDA: biotech friend or foe?

Fourth-quarter biotech job picture.

3-D biotech: tissue engineering.

Problematic comparisons.

Public biotech in 2014--the numbers.

2015--another banner year for biotech.

Taiwan biotech buoyed by colossal financings.

Suggest Documents

Malaria vaccines: the failed promise.

Vaccines: facing complex problems with the promise of immunology.

Peptide vaccines for hematological malignancies: a missed promise?

Emerging cancer vaccines: the promise of genetic vectors.

The promise and challenge of epitope-focused vaccines.

Patent patterns in biotech.

Biotech grows in Hong Kong.

Bridging tech and biotech.

Biotech lobby pressure EC.

2Q14-Biotech corrected.

Fourth-quarter biotech job picture.

Do recombinant-engineered nanoparticle vaccines hold promise for the prevention of respiratory syncytial virus?

Broadly neutralizing antibodies and the promise of universal vaccines: where are we now?

South Asia symposium on pneumococcal disease and the promise of vaccines - Meeting report.

Second-quarter biotech job picture.

2013--Biotech back in the saddle.

Public biotech 2013--the numbers.

FDA: biotech friend or foe?

Fourth-quarter biotech job picture.

3-D biotech: tissue engineering.

Problematic comparisons.

Public biotech in 2014--the numbers.

2015--another banner year for biotech.

Taiwan biotech buoyed by colossal financings.

Biotech vaccines' problematic promise.

Recommend Documents

Follow Us